Form D · Biotechnology

Jnana Therapeutics Inc.

Boston, MA · CIK 0001879148

Offering snapshot reported Jan 26, 2024 · SEC filing

Reported sold: $107M
Investors reported: 8
Minimum accepted: $0
First sale: Nov 2, 2022

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$59,999,998 → $106,999,997

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jan 26, 2024	Amendment	$106,999,997	$46,999,999vs Nov 16, 2022	8	SEC filing
Nov 16, 2022	Initial	$59,999,998	No comparison	8	SEC filing
Aug 24, 2021	Initial	$50,000,000	No comparison	14	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-465004

Source: Form D, filed Jan 26, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Joel Barrish	Executive
Caroline Stark Beer	Executive
Brian M. Cali	Director
Annie C. Chen	Director
Matthew Hammond	Director
Kevin J. Kinsella	Director
Joanne D. Kotz	Director, Executive
Terrance G. Mc Guire	Director
Donald W. Nicholson	Director
Douglas W. Pagan	Executive
Ronald C. Renaud, Jr.	Director
Carlo Rizzuto	Director
Stuart Schreiber	Director
George Vratsanos	Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

One Design Center Place Suite 19 400
Boston, MA, 02210